RE: RNS30 Jan 2025 16:41
I've held TRX for a few years now, and have always been very positive on the company, but today's RNS struck a slightly sour note. The RNS seems worded in such a way as to obscure the disappointment of H2.
Going from the '24 Interims, where the 2 main parts of the business generated $14.7m revenue, that means H2 generated $13.7m, a drop in growth for the half-year.
TRX has previously boasted of its consecutive half-yearly growth numbers, but today's RNS only mentions growth in full years (8% growth for FY24, vs 20% at the half-year).
I have never liked the emphasis on company profitability based on EBITDA, when in fact the company is still running at a loss. I had a discussion with another shareholder on here in the past about the difference between EBITDA-positive and net cash positive, and the quote about how Charlie Munger substitutes the phrase "bulls h!t earnings" whenever he read "EBITDA earnings".
There have been a lot of sells today, some of which are mine, but they seem to have been absorbed, suggesting a background buyer. There is still a lot to like about TRX, and it may prove that the company is in the process of being bought out for a price higher than 58p, but in the short- to medium term I have concerns. I want to see more meat on the bone regarding the H2 drop. A loss of donors? Are the customers cutting back on orders due to global financial concerns?
It is tough to see what would cause a share price rise in the short to medium term, takeover aside, so it might come down to the next interim reporting period to see a return to growth in the business and the share price.